Idogen will during the conference meet with the company's scientific advisers and representatives from the all the clinical centers that will conduct the company's clinical phase I/IIa study for IDO 8. The discussions will touch on both new scientific advances in the field and the ongoing development of the company's cell therapy, IDO 8. Idogen will be represented on site by the company's CEO Anders Karlsson and Hanjing Xie, Idogen's Chief Medical Officer.

"ISTH 2022 is an excellent opportunity for us to meet our international advisors in a physical meeting and discuss both the development of IDO 8 but also Idogen's strategic trade-offs in the continued development of our unique cell therapies. We look forward to meetings with rewarding conversations ", says Anders Karlsson, CEO of Idogen.

Idogen develops tolerogenic cell therapies with the potential to restore the immune system's tolerance in order to counteract its attack on biological drugs, transplanted organs or the body's own tissue. The company's most advanced project IDO 8 aims to treat hemophilia patients who have developed an unwanted immune response to their vital treatment with FVIII-koncentrate. Idogen has received approval from the Swedish and Norwegian pharmaceutical authorities to initiate a first clinical phase I/IIa study with IDO 8 in patients with severe hemophilia A and neutralizing antibodies against their FVIII treatment.

For further information, please contact:

Anders Karlsson, CEO, Idogen AB

Phone: +46 70918 00 10

Email: anders.karlsson@idogen.com

Certified Adviser:
The companies Certified Adviser is Vator Securities AB. Contact information : Vator Securities AB, Kungsgatan 34, SE-111 35 Stockholm, Email: ca@vatorsec.se.Tel: +46 (0)8-580 065 99

The information was submitted for publication, through the agency of the contact persons set out above, on 11 July 2022 at 08:44 CET.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Idogen (Nasdaq First Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company's most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company's second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own

cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care. More information about Idogen is available via https://www.idogen.com